Review



mad2l2 a4630 antibody  (ABclonal Biotechnology)


Bioz Verified Symbol ABclonal Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ABclonal Biotechnology mad2l2 a4630 antibody
    AURKB interacts with and promotes the expression of <t>MAD2L2.</t> A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)
    Mad2l2 A4630 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mad2l2+a4630+antibody/mad2l2+a4630+antibody/pmc10956193-80-17-20
    Average 90 stars, based on 1 article reviews
    mad2l2 a4630 antibody - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2"

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

    Journal: Journal of Translational Medicine

    doi: 10.1186/s12967-024-05099-6

    AURKB interacts with and promotes the expression of MAD2L2. A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)
    Figure Legend Snippet: AURKB interacts with and promotes the expression of MAD2L2. A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Techniques Used: Expressing, Western Blot, Co-Immunoprecipitation Assay, Staining, Microscopy

    AURKB ablation upregulates the p53 pathway and suppresses BC cell progression via MAD2L2. A - B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay demonstrated the capacity of migration. H The transwell assay demonstrated the capacity of invasion. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)
    Figure Legend Snippet: AURKB ablation upregulates the p53 pathway and suppresses BC cell progression via MAD2L2. A - B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay demonstrated the capacity of migration. H The transwell assay demonstrated the capacity of invasion. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Techniques Used: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Wound Healing Assay, Migration, Transwell Assay, Microscopy

    Ablation of MAD2L2 suppresses BC cell progression via p53 DDR pathway. A , B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay for T24 and 5637 cells. H The transwell assay for T24 and 5637 cells. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)
    Figure Legend Snippet: Ablation of MAD2L2 suppresses BC cell progression via p53 DDR pathway. A , B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay for T24 and 5637 cells. H The transwell assay for T24 and 5637 cells. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Techniques Used: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Wound Healing Assay, Transwell Assay, Microscopy

    AURKB promotes BC growth and downregulats p53 DDR pahway by regulating MAD2L2 expression in vivo. A Images of dissected T24 xenograft tumors. B , C Tumor volume and weight in each group. D Representative images of IHC staining for MAD2L2, KI67, CyclinD1 and p53 in each group. E Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression in each group (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)
    Figure Legend Snippet: AURKB promotes BC growth and downregulats p53 DDR pahway by regulating MAD2L2 expression in vivo. A Images of dissected T24 xenograft tumors. B , C Tumor volume and weight in each group. D Representative images of IHC staining for MAD2L2, KI67, CyclinD1 and p53 in each group. E Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression in each group (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Techniques Used: Expressing, In Vivo, Immunohistochemistry, Western Blot, Microscopy

    Related Articles

    Expressing:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Western Blot:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Co-Immunoprecipitation Assay:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Staining:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Microscopy:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    CCK-8 Assay:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Cell Cycle Assay:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Flow Cytometry:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Wound Healing Assay:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Migration:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Transwell Assay:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    In Vivo:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Immunohistochemistry:

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: The following primary antibodies were used in the present study: AURKB (1:1000, A1020, ABclonal, Wuhan, China), MAD2L2 (1:1000, A4630, ABclonal), Cyclin D1 (1:1000, A19038, ABclonal), p53 (1:1000, ab32049, Abcam, UK), p21 (1:1000, A1483, ABclonal), γH2A.X (1:5000, T56572, Abmart, Shanghai, China), β-Tubulin (1:5000, M20005, Abmart).

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).



    Similar Products

    mad2l2 a4630 antibody  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology mad2l2 a4630 antibody
    AURKB interacts with and promotes the expression of <t>MAD2L2.</t> A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)
    Mad2l2 A4630 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mad2l2+a4630+antibody/mad2l2+a4630+antibody/pmc10956193-80-17-20
    Average 90 stars, based on 1 article reviews
    mad2l2 a4630 antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    AURKB interacts with and promotes the expression of MAD2L2. A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Journal: Journal of Translational Medicine

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

    doi: 10.1186/s12967-024-05099-6

    Figure Lengend Snippet: AURKB interacts with and promotes the expression of MAD2L2. A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Techniques: Expressing, Western Blot, Co-Immunoprecipitation Assay, Staining, Microscopy

    AURKB ablation upregulates the p53 pathway and suppresses BC cell progression via MAD2L2. A - B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay demonstrated the capacity of migration. H The transwell assay demonstrated the capacity of invasion. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Journal: Journal of Translational Medicine

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

    doi: 10.1186/s12967-024-05099-6

    Figure Lengend Snippet: AURKB ablation upregulates the p53 pathway and suppresses BC cell progression via MAD2L2. A - B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay demonstrated the capacity of migration. H The transwell assay demonstrated the capacity of invasion. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Techniques: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Wound Healing Assay, Migration, Transwell Assay, Microscopy

    Ablation of MAD2L2 suppresses BC cell progression via p53 DDR pathway. A , B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay for T24 and 5637 cells. H The transwell assay for T24 and 5637 cells. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Journal: Journal of Translational Medicine

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

    doi: 10.1186/s12967-024-05099-6

    Figure Lengend Snippet: Ablation of MAD2L2 suppresses BC cell progression via p53 DDR pathway. A , B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay for T24 and 5637 cells. H The transwell assay for T24 and 5637 cells. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Techniques: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Wound Healing Assay, Transwell Assay, Microscopy

    AURKB promotes BC growth and downregulats p53 DDR pahway by regulating MAD2L2 expression in vivo. A Images of dissected T24 xenograft tumors. B , C Tumor volume and weight in each group. D Representative images of IHC staining for MAD2L2, KI67, CyclinD1 and p53 in each group. E Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression in each group (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Journal: Journal of Translational Medicine

    Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

    doi: 10.1186/s12967-024-05099-6

    Figure Lengend Snippet: AURKB promotes BC growth and downregulats p53 DDR pahway by regulating MAD2L2 expression in vivo. A Images of dissected T24 xenograft tumors. B , C Tumor volume and weight in each group. D Representative images of IHC staining for MAD2L2, KI67, CyclinD1 and p53 in each group. E Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression in each group (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

    Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

    Techniques: Expressing, In Vivo, Immunohistochemistry, Western Blot, Microscopy